Response to: "Comment on Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma".
作者信息
Famularo Simone, Donadon Matteo, Cipriani Federica, Aldrighetti Luca, Trevisani Franco, Torzilli Guido
机构信息
From the Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.
Department of Hepatobiliary and General Surgery, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
出版信息
Ann Surg Open. 2023 Mar 13;4(1):e251. doi: 10.1097/AS9.0000000000000251. eCollection 2023 Mar.
Abstract
摘要
相似文献
1
Response to: "Comment on Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma".对《晚期非转移性肝细胞癌肝切除术与索拉非尼治疗的评论》的回应
Ann Surg Open. 2023 Mar 13;4(1):e251. doi: 10.1097/AS9.0000000000000251. eCollection 2023 Mar.
2
Comment on "Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma".关于“晚期非转移性肝细胞癌的肝切除术与索拉非尼治疗对比”的评论
Ann Surg Open. 2023 Jan 30;4(1):e254. doi: 10.1097/AS9.0000000000000254. eCollection 2023 Mar.
3
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.肝切除术与索拉非尼治疗晚期非转移性肝细胞癌的真实世界多中心加权比较
Ann Surg. 2022 Apr 1;275(4):743-752. doi: 10.1097/SLA.0000000000005373.
4
Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.索拉非尼对一名复发性肝细胞癌患者的完全缓解。
World J Gastroenterol. 2014 Oct 21;20(39):14505-9. doi: 10.3748/wjg.v20.i39.14505.
5
The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.索拉非尼治疗不可切除肝细胞癌的疗效：转化性和挽救性肝切除术的经验
Anticancer Res. 2018 Jan;38(1):501-507. doi: 10.21873/anticanres.12250.
6
Advanced Recurrent Hepatocellular Carcinoma: Treatment with Sorafenib Alone or in Combination with Transarterial Chemoembolization and Radiofrequency Ablation.晚期复发性肝细胞癌：索拉非尼单药或联合经动脉化疗栓塞和射频消融治疗。
Radiology. 2018 May;287(2):705-714. doi: 10.1148/radiol.2018171541. Epub 2018 Feb 1.
7
Concurrent Sorafenib and Radiotherapy versus Radiotherapy Alone for Locally Advanced Hepatocellular Carcinoma: A Propensity-Matched Analysis.索拉非尼与放疗联合治疗与单纯放疗治疗局部晚期肝细胞癌的倾向评分匹配分析
J Hepatocell Carcinoma. 2021 Aug 18;8:963-973. doi: 10.2147/JHC.S323302. eCollection 2021.
8
Hepatectomy combined with sorafenib in patients with intermediate-advanced hepatocellullar carcinoma.肝切除术联合索拉非尼治疗中晚期肝细胞癌患者。
J BUON. 2019 Jul-Aug;24(4):1382-1389.
9
Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature.采用包括降低剂量索拉非尼在内的多学科治疗方案治疗晚期肝细胞癌的长期完全缓解：病例报告及文献综述
World J Surg Oncol. 2015 Apr 9;13:144. doi: 10.1186/s12957-015-0559-9.
10
Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.索拉非尼诱导晚期肝细胞癌伴多发肺转移和静脉瘤栓实现根治性切除的完全病理缓解。
Clin J Gastroenterol. 2015 Oct;8(5):300-5. doi: 10.1007/s12328-015-0594-7. Epub 2015 Aug 7.
本文引用的文献
1
Conversion surgery after preoperative therapy for advanced hepatocellular carcinoma in the era of molecular targeted therapy and immune checkpoint inhibitors.术前治疗后转化手术治疗分子靶向治疗和免疫检查点抑制剂时代的晚期肝细胞癌。
J Hepatobiliary Pancreat Sci. 2022 Jul;29(7):732-740. doi: 10.1002/jhbp.1135. Epub 2022 Mar 31.
2
Hepatectomy Versus Sorafenib in Advanced Nonmetastatic Hepatocellular Carcinoma: A Real-life Multicentric Weighted Comparison.肝切除术与索拉非尼治疗晚期非转移性肝细胞癌的真实世界多中心加权比较
Ann Surg. 2022 Apr 1;275(4):743-752. doi: 10.1097/SLA.0000000000005373.
3
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial.可切除肝细胞癌中围手术期纳武单抗单药治疗与纳武单抗联合伊匹单抗治疗的随机、开放标签、2 期临床试验。
Lancet Gastroenterol Hepatol. 2022 Mar;7(3):208-218. doi: 10.1016/S2468-1253(21)00427-1. Epub 2022 Jan 20.
4
BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update.BCLC 策略用于预后预测和治疗推荐：2022 年更新版。
J Hepatol. 2022 Mar;76(3):681-693. doi: 10.1016/j.jhep.2021.11.018. Epub 2021 Nov 19.
5
Treatment of Hepatocellular Carcinoma in the Precision Medicine Era: From Treatment Stage Migration to Therapeutic Hierarchy.精准医学时代肝细胞癌的治疗：从治疗阶段转移到治疗层次。
Hepatology. 2020 Dec;72(6):2206-2218. doi: 10.1002/hep.31187. Epub 2020 Oct 26.
6
Survival benefit of liver resection for hepatocellular carcinoma associated with portal vein invasion.肝切除术治疗伴有门静脉侵犯的肝细胞癌的生存获益。
J Hepatol. 2016 Nov;65(5):938-943. doi: 10.1016/j.jhep.2016.05.044. Epub 2016 Jun 4.
7
The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments.倾向评分方法在生存或事件发生时间结局中的应用：报告与随机试验中使用的效应测量指标相似的指标。
Stat Med. 2014 Mar 30;33(7):1242-58. doi: 10.1002/sim.5984. Epub 2013 Sep 30.
8
A snapshot of the effective indications and results of surgery for hepatocellular carcinoma in tertiary referral centers: is it adherent to the EASL/AASLD recommendations?: an observational study of the HCC East-West study group.在三级转诊中心，手术治疗肝细胞癌的有效适应证和结果概览：是否符合 EASL/AASLD 建议？：HCC 东西研究组的一项观察性研究。
Ann Surg. 2013 May;257(5):929-37. doi: 10.1097/SLA.0b013e31828329b8.
9
Hepatectomy for stage B and stage C hepatocellular carcinoma in the Barcelona Clinic Liver Cancer classification: results of a prospective analysis.巴塞罗那临床肝癌分期中B期和C期肝细胞癌的肝切除术：一项前瞻性分析结果
Arch Surg. 2008 Nov;143(11):1082-90. doi: 10.1001/archsurg.143.11.1082.
10
Sorafenib in advanced hepatocellular carcinoma.索拉非尼用于晚期肝细胞癌
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件